AP
Apogee Therapeutics, Inc.
APGE · NASDAQ
$135.07 +0.01% (+$0.01)
1M +0.21%
Market Cap $8.36B
P/E Ratio -
Div. Yield -
ROE 29.88%
Piotroski F-Score Weak
2/9Valuation
13 /100
Expensive P/B 7.00x
P/E N/A
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 85.30%
EPS growth N/A
FCF growth N/A
Profitability
-
N/A Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
0 /100
Poor ROIC 25.25%
Asset turnover 0.00x
ROE 29.88%
Debt
69 /100
Low Debt/Equity 0.01x
Int. coverage -185.14x
Current ratio 26.44x
Stability
33 /100
Unstable Beta 0.34x
Profitable years 0
EPS volatility 44.58%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o APGE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Thomas Henderson
Employees
261
Headquarters
Waltham
Prihajajoči dogodki
09 NOV.
Earnings
Upcoming earnings report